Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    12941809 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Sorafenib (BAY 43-9006) to Treat Children With Solid Tumors or Leukemias
Conditions: Leukemia;   With AML and FLT3-ITD Mutations
Intervention: Drug: Sorafenib

Indicates status has not been verified in more than two years